ROCKLAND, Mass., Jan. 27, 2016 /PRNewswire/ -- EMD Serono, the North America biopharma business of Merck KGaA, Darmstadt, Germany, announced today that Gary Zieziula has been appointed President and Managing Director, North America, of the company. In this role, he will be responsible for all areas of the company's business, including driving overall strategic direction and maximizing growth across the region.
EMD Serono is a leader in specialty care, integrating cutting-edge science, innovative medicines and devices, as well as industry-leading patient support and access programs.
Mr. Zieziula joined EMD Serono in 2014 as Chief Commercial Officer, responsible for the performance of the company's franchises in multiple sclerosis, fertility, endocrinology and oncology. He has more than 30 years of experience in the pharmaceutical industry, including senior level positions at MSD, Bristol-Myers Squibb, Roche and AMAG Pharmaceuticals.
"As we look to grow our biopharma business in North America, including our progress in oncology and immuno-oncology, Gary's vision, experience and customer-centric approach are critical to lead the company forward," said Simon Sturge, Chief Operating Officer, Healthcare, Merck KGaA, Darmstadt, Germany.
"I'm honored to move into this role and continue to collaborate with our outstanding local and global teams, as we work with a sense of urgency and focus on finding and delivering solutions to patients with difficult-to-treat, specialty care diseases and conditions," said Mr. Zieziula.
Mr. Zieziula holds a Bachelor of Science degree from the State University of New York at Buffalo and an MBA from Canisius College.
About EMD Serono, Inc.
EMD Serono is the North America biopharma business of Merck KGaA, Darmstadt, Germany — a leading science and technology company — focused exclusively on specialty care. For more than 40 years, the business has integrated cutting-edge science, innovative products and industry-leading patient support and access programs. EMD Serono has deep expertise in neurology, fertility and endocrinology, as well as a robust pipeline of potential therapies in oncology, immuno-oncology and immunology as R&D focus areas. Today, the business has more than 1,100 employees around the country with commercial, clinical and research operations based in the company's home state of Massachusetts.
About Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life — from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2014, Merck KGaA, Darmstadt, Germany generated sales of €11.3 billion in 66 countries.
Founded in 1668, Merck KGaA, Darmstadt, Germany is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck KGaA, Darmstadt, Germany holds the rights to the Merck KGaA, Darmstadt, Germany name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.
All Merck KGaA, Darmstadt, Germany press releases are distributed by e-mail at the same time they become available on the EMD Group Website. In case you are a resident of the USA or Canada please go to www.emdgroup.com/subscribe to register again for your online subscription of this service as our newly introduced geo-targeting requires new links in the email. You may later change your selection or discontinue this service.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/gary-zieziula-appointed-president-and-managing-director-of-emd-serono-300210429.html
SOURCE EMD Serono